CAR T Cells Treat Lupus in Mice
CAR T Cells Treat Lupus in Mice
T cells modified to target disease-contributing B cells improved survival in two mouse models of the autoimmune disease.
CAR T Cells Treat Lupus in Mice
CAR T Cells Treat Lupus in Mice

T cells modified to target disease-contributing B cells improved survival in two mouse models of the autoimmune disease.

T cells modified to target disease-contributing B cells improved survival in two mouse models of the autoimmune disease.

CAR T cells
<em>Nature&nbsp;</em>Retracts Paper on Delivery System for CAR T Immunotherapy
Nature Retracts Paper on Delivery System for CAR T Immunotherapy
Diana Kwon | Feb 20, 2019
The manuscript had amassed more than 50 comments about problematic figures and data on PubPeer.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.
Two CAR T-Cell Therapies Greenlighted in Europe
Two CAR T-Cell Therapies Greenlighted in Europe
Jef Akst | Aug 28, 2018
Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 
Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Katarina Zimmer | Jul 6, 2018
Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.
New Insights to Improve CAR T Cells’ Safety
New Insights to Improve CAR T Cells’ Safety
Vicki Brower | Jun 5, 2018
Drugs approved to treat rheumatoid arthritis block cytokines, the molecules responsible for severe side effects from the immunotherapy, and reduce symptoms in mice.
World’s Largest Cell and Gene Therapy Plant Opens
World’s Largest Cell and Gene Therapy Plant Opens
Catherine Offord | Apr 11, 2018
Lonza will employ more than 200 full-time staff to work at the Texas-based facility, the company says.
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Katarina Zimmer | Jan 23, 2018
Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.
Gilead’s CAR T-Cell Therapy Administered to Just Five Patients in Two Months
Gilead’s CAR T-Cell Therapy Administered to Just Five Patients in Two Months
Catherine Offord | Dec 17, 2017
More than 200 people are on waiting lists for the $373,000 treatment as hospitals try to work around problems with insurers. 
Antiviral Immunotherapy Comes of Age
Antiviral Immunotherapy Comes of Age
Lucas Laursen | Dec 4, 2017
T-cell therapies are not just for cancer. Researchers are also advancing immunotherapy methods to protect bone marrow transplant patients from viral infections.